Pay in 4 interest-free payments of $5.84 Learn more
Ships within 48 hours · Estimated delivery Oct 30 - Nov 4
Within the last decade, novel therapies, including glucagon-like peptide 1 receptor agonists, have been studied for their use as adjuvants to weight loss therapy
Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are an emerging class of glucose-lowering drugs that are increasingly used in the treatment of type 2 diabetes (T2D) and obesity
GLP-1 receptor agonists and mental health: A systematic review of neuropsychiatric effects
Landmark clinical trials, such as the STEP programme for semaglutide published in The New England Journal of Medicine, have demonstrated that these medications can lead to average weight loss of 15% or more when combined with lifestyle changes, a level of efficacy previously achievable only through bariatric surgery
If you havent noticed a decrease in appetite after several weeks, or if you have any questions or concerns about your medication, please schedule a follow-up with our providers
